Serum levels of interleukin-17, -18, -22, and -25 in patients with bullous pemphigoid before and after treatment
ObjectiveThis study aimed to explore the relationship between serum levels of interleukin-17 (IL-17), interleukin-18 (IL-18), interleukin-22 (IL-22), interleukin-25 (IL-25), anti-BP180 antibodies, anti-BP230 antibodies, and immunoglobulin E (IgE) and the percentage of eosinophils (EOS) in peripheral...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1559372/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849729568065191936 |
|---|---|
| author | Xinyi Hong Xinyi Hong Xinyi Hong Xinyi Hong Xiuqin Wang Xiuqin Wang Xiuqin Wang Xiuqin Wang Yin Cheng Yin Cheng Yin Cheng Yin Cheng Hanqing Song Hanqing Song Hanqing Song Hanqing Song Congcong Xu Congcong Xu Congcong Xu Congcong Xu Peiguang Wang Peiguang Wang Peiguang Wang Peiguang Wang |
| author_facet | Xinyi Hong Xinyi Hong Xinyi Hong Xinyi Hong Xiuqin Wang Xiuqin Wang Xiuqin Wang Xiuqin Wang Yin Cheng Yin Cheng Yin Cheng Yin Cheng Hanqing Song Hanqing Song Hanqing Song Hanqing Song Congcong Xu Congcong Xu Congcong Xu Congcong Xu Peiguang Wang Peiguang Wang Peiguang Wang Peiguang Wang |
| author_sort | Xinyi Hong |
| collection | DOAJ |
| description | ObjectiveThis study aimed to explore the relationship between serum levels of interleukin-17 (IL-17), interleukin-18 (IL-18), interleukin-22 (IL-22), interleukin-25 (IL-25), anti-BP180 antibodies, anti-BP230 antibodies, and immunoglobulin E (IgE) and the percentage of eosinophils (EOS) in peripheral blood and disease activity and severity in bullous pemphigoid (BP) patients.MethodsBlood samples from 61 BP inpatients were collected on the first day of admission and again 1 week after systemic corticosteroid treatment. Additionally, blood specimens were collected from 61 healthy controls. The concentrations of IL-17, IL-18, IL-22, IL-25, IgE, and anti-BP180 or anti-BP230 antibodies were measured using ELISA kits. Various statistical methods were used, including the Wilcoxon test, multifactorial logistic regression, ROC survival curve, and Spearman’s correlation analysis.ResultsThe mean serum levels of IL-17, IL-18, IL-22, IL-25, and EOS percentage in BP patients were higher than those in healthy controls (all p < 0.001), and all of these levels decreased after treatment (all p < 0.001). There was no statistically significant difference in the titer of anti-BP180 or anti-BP230 antibodies before and after treatment. A binary multivariate logistic regression analysis indicated the statistically significant effect of IL-18, IL-25, or EOS on BP (p < 0.001). Spearman’s correlation analysis revealed that the serum levels of IL-17, IL-22, or IL-25 were all strongly correlated with the involved surface area (p < 0.001). In addition, the serum level of IL-17 and the percentage of EOS were associated with the titer of anti-BP180 antibodies (p < 0.05).ConclusionIL-17, IL-18, IL-22, IL-25, or EOS may be involved in the development of BP, and can be used as biological indicators for monitoring disease severity. |
| format | Article |
| id | doaj-art-c3b73811bc4a4d0bbd357478c20cc257 |
| institution | DOAJ |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-c3b73811bc4a4d0bbd357478c20cc2572025-08-20T03:09:11ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-07-011210.3389/fmed.2025.15593721559372Serum levels of interleukin-17, -18, -22, and -25 in patients with bullous pemphigoid before and after treatmentXinyi Hong0Xinyi Hong1Xinyi Hong2Xinyi Hong3Xiuqin Wang4Xiuqin Wang5Xiuqin Wang6Xiuqin Wang7Yin Cheng8Yin Cheng9Yin Cheng10Yin Cheng11Hanqing Song12Hanqing Song13Hanqing Song14Hanqing Song15Congcong Xu16Congcong Xu17Congcong Xu18Congcong Xu19Peiguang Wang20Peiguang Wang21Peiguang Wang22Peiguang Wang23Department of Dermatology, First Affiliated Hospital of Anhui Medical University, Hefei, ChinaInstitute of Dermatology, Anhui Medical University, Hefei, ChinaKey Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei, ChinaCollaborative Innovation Center of Complex and Severe Skin Disease, Anhui Medical University, Hefei, ChinaDepartment of Dermatology, First Affiliated Hospital of Anhui Medical University, Hefei, ChinaInstitute of Dermatology, Anhui Medical University, Hefei, ChinaKey Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei, ChinaCollaborative Innovation Center of Complex and Severe Skin Disease, Anhui Medical University, Hefei, ChinaDepartment of Dermatology, First Affiliated Hospital of Anhui Medical University, Hefei, ChinaInstitute of Dermatology, Anhui Medical University, Hefei, ChinaKey Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei, ChinaCollaborative Innovation Center of Complex and Severe Skin Disease, Anhui Medical University, Hefei, ChinaInstitute of Dermatology, Anhui Medical University, Hefei, ChinaKey Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei, ChinaCollaborative Innovation Center of Complex and Severe Skin Disease, Anhui Medical University, Hefei, ChinaWuxi Ninth People's Hospital, Soochow University, Wuxi, ChinaDepartment of Dermatology, First Affiliated Hospital of Anhui Medical University, Hefei, ChinaInstitute of Dermatology, Anhui Medical University, Hefei, ChinaKey Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei, ChinaCollaborative Innovation Center of Complex and Severe Skin Disease, Anhui Medical University, Hefei, ChinaDepartment of Dermatology, First Affiliated Hospital of Anhui Medical University, Hefei, ChinaInstitute of Dermatology, Anhui Medical University, Hefei, ChinaKey Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei, ChinaCollaborative Innovation Center of Complex and Severe Skin Disease, Anhui Medical University, Hefei, ChinaObjectiveThis study aimed to explore the relationship between serum levels of interleukin-17 (IL-17), interleukin-18 (IL-18), interleukin-22 (IL-22), interleukin-25 (IL-25), anti-BP180 antibodies, anti-BP230 antibodies, and immunoglobulin E (IgE) and the percentage of eosinophils (EOS) in peripheral blood and disease activity and severity in bullous pemphigoid (BP) patients.MethodsBlood samples from 61 BP inpatients were collected on the first day of admission and again 1 week after systemic corticosteroid treatment. Additionally, blood specimens were collected from 61 healthy controls. The concentrations of IL-17, IL-18, IL-22, IL-25, IgE, and anti-BP180 or anti-BP230 antibodies were measured using ELISA kits. Various statistical methods were used, including the Wilcoxon test, multifactorial logistic regression, ROC survival curve, and Spearman’s correlation analysis.ResultsThe mean serum levels of IL-17, IL-18, IL-22, IL-25, and EOS percentage in BP patients were higher than those in healthy controls (all p < 0.001), and all of these levels decreased after treatment (all p < 0.001). There was no statistically significant difference in the titer of anti-BP180 or anti-BP230 antibodies before and after treatment. A binary multivariate logistic regression analysis indicated the statistically significant effect of IL-18, IL-25, or EOS on BP (p < 0.001). Spearman’s correlation analysis revealed that the serum levels of IL-17, IL-22, or IL-25 were all strongly correlated with the involved surface area (p < 0.001). In addition, the serum level of IL-17 and the percentage of EOS were associated with the titer of anti-BP180 antibodies (p < 0.05).ConclusionIL-17, IL-18, IL-22, IL-25, or EOS may be involved in the development of BP, and can be used as biological indicators for monitoring disease severity.https://www.frontiersin.org/articles/10.3389/fmed.2025.1559372/fullIL-17IL-18IL-22IL-25EOSBP180 antibodies |
| spellingShingle | Xinyi Hong Xinyi Hong Xinyi Hong Xinyi Hong Xiuqin Wang Xiuqin Wang Xiuqin Wang Xiuqin Wang Yin Cheng Yin Cheng Yin Cheng Yin Cheng Hanqing Song Hanqing Song Hanqing Song Hanqing Song Congcong Xu Congcong Xu Congcong Xu Congcong Xu Peiguang Wang Peiguang Wang Peiguang Wang Peiguang Wang Serum levels of interleukin-17, -18, -22, and -25 in patients with bullous pemphigoid before and after treatment Frontiers in Medicine IL-17 IL-18 IL-22 IL-25 EOS BP180 antibodies |
| title | Serum levels of interleukin-17, -18, -22, and -25 in patients with bullous pemphigoid before and after treatment |
| title_full | Serum levels of interleukin-17, -18, -22, and -25 in patients with bullous pemphigoid before and after treatment |
| title_fullStr | Serum levels of interleukin-17, -18, -22, and -25 in patients with bullous pemphigoid before and after treatment |
| title_full_unstemmed | Serum levels of interleukin-17, -18, -22, and -25 in patients with bullous pemphigoid before and after treatment |
| title_short | Serum levels of interleukin-17, -18, -22, and -25 in patients with bullous pemphigoid before and after treatment |
| title_sort | serum levels of interleukin 17 18 22 and 25 in patients with bullous pemphigoid before and after treatment |
| topic | IL-17 IL-18 IL-22 IL-25 EOS BP180 antibodies |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2025.1559372/full |
| work_keys_str_mv | AT xinyihong serumlevelsofinterleukin171822and25inpatientswithbullouspemphigoidbeforeandaftertreatment AT xinyihong serumlevelsofinterleukin171822and25inpatientswithbullouspemphigoidbeforeandaftertreatment AT xinyihong serumlevelsofinterleukin171822and25inpatientswithbullouspemphigoidbeforeandaftertreatment AT xinyihong serumlevelsofinterleukin171822and25inpatientswithbullouspemphigoidbeforeandaftertreatment AT xiuqinwang serumlevelsofinterleukin171822and25inpatientswithbullouspemphigoidbeforeandaftertreatment AT xiuqinwang serumlevelsofinterleukin171822and25inpatientswithbullouspemphigoidbeforeandaftertreatment AT xiuqinwang serumlevelsofinterleukin171822and25inpatientswithbullouspemphigoidbeforeandaftertreatment AT xiuqinwang serumlevelsofinterleukin171822and25inpatientswithbullouspemphigoidbeforeandaftertreatment AT yincheng serumlevelsofinterleukin171822and25inpatientswithbullouspemphigoidbeforeandaftertreatment AT yincheng serumlevelsofinterleukin171822and25inpatientswithbullouspemphigoidbeforeandaftertreatment AT yincheng serumlevelsofinterleukin171822and25inpatientswithbullouspemphigoidbeforeandaftertreatment AT yincheng serumlevelsofinterleukin171822and25inpatientswithbullouspemphigoidbeforeandaftertreatment AT hanqingsong serumlevelsofinterleukin171822and25inpatientswithbullouspemphigoidbeforeandaftertreatment AT hanqingsong serumlevelsofinterleukin171822and25inpatientswithbullouspemphigoidbeforeandaftertreatment AT hanqingsong serumlevelsofinterleukin171822and25inpatientswithbullouspemphigoidbeforeandaftertreatment AT hanqingsong serumlevelsofinterleukin171822and25inpatientswithbullouspemphigoidbeforeandaftertreatment AT congcongxu serumlevelsofinterleukin171822and25inpatientswithbullouspemphigoidbeforeandaftertreatment AT congcongxu serumlevelsofinterleukin171822and25inpatientswithbullouspemphigoidbeforeandaftertreatment AT congcongxu serumlevelsofinterleukin171822and25inpatientswithbullouspemphigoidbeforeandaftertreatment AT congcongxu serumlevelsofinterleukin171822and25inpatientswithbullouspemphigoidbeforeandaftertreatment AT peiguangwang serumlevelsofinterleukin171822and25inpatientswithbullouspemphigoidbeforeandaftertreatment AT peiguangwang serumlevelsofinterleukin171822and25inpatientswithbullouspemphigoidbeforeandaftertreatment AT peiguangwang serumlevelsofinterleukin171822and25inpatientswithbullouspemphigoidbeforeandaftertreatment AT peiguangwang serumlevelsofinterleukin171822and25inpatientswithbullouspemphigoidbeforeandaftertreatment |